Long-term performance of the fructosamine assay

Area of Science:

• Clinical Chemistry
• Endocrinology
• Diabetes Mellitus Research

Background:

• The fructosamine assay measures glycated proteins, offering an alternative to HbA1 for assessing long-term glycemic control.
• Understanding the long-term performance and interpretation of fructosamine levels is crucial for effective diabetes management.

Purpose of the Study:

• To evaluate the long-term performance and precision of the fructosamine assay.
• To define the interpretation of varying fructosamine concentrations compared to HbA1 in both insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) patients.
• To assess the diagnostic accuracy of fructosamine in predicting glycemic control levels.

Main Methods:

• Assessed between-batch imprecision of the fructosamine assay over five months.
• Monitored in vivo variation of fructosamine concentration in stable diabetic patients over 8-18 weeks.
• Correlated fructosamine levels with haemoglobin A1 (HbA1) in IDDM and NIDDM cohorts.
• Determined specificity and sensitivity of fructosamine for predicting glycemic control based on HbA1 cut-off points.

Main Results:

• The fructosamine assay demonstrated good between-batch imprecision (CV 2.5%-3.6%) and in vivo stability (2.3%-7.1%).
• Strong correlations were observed between fructosamine and HbA1 in both IDDM (r=0.701) and NIDDM (r=0.764) patients.
• Significant discordancy in patient classification occurred, with 22.5% in NIDDM and 31.8% in IDDM classified differently by fructosamine versus HbA1.

Conclusions:

• The fructosamine assay exhibits reliable long-term performance and stability.
• Fructosamine assessment of diabetic control may differ from HbA1, particularly in IDDM patients.
• Fructosamine and HbA1 should be utilized as complementary tests for comprehensive diabetes management rather than as alternatives.